From August 22 - 24, the 18th VUNA Annual Scientific Conference and the 16th Thua Thien Hue Urology and Nephrology Association Scientific Conference (referred to as HueUNA 2024) were held in Hue City. The conference had the participation of many leading domestic and international experts with hundreds of scientific reports and many satellite conference sessions.
One of the outstanding sessions that received the attention of many physicians was "Nephrology session - Update on new advances in the field of Nephrology", in which the role of screening and early detection of diseases Chronic kidney disease is emphasized and the SGLT2 inhibitor group is considered a new pillar, opening up hope for chronic kidney disease patients across the country.
During the past 2 years, the Vietnam Association of Urology and Nephrology has continuously implemented many training programs to improve early diagnosis and treatment of chronic kidney disease to help improve the quality of life of patients, with the companionship of pharmaceutical companies, including Boehringer Ingelheim.
Professor. Vo Tam, Vice President of the Vietnam Association of Urology and Nephrology, shared: “The year 2024 is considered a turning point for the specialty of nephrology when both in the world and in Vietnam, treatment recommendations and directions are announced. Practice guide, is the basis to help clinicians detect early and treat promptly, improving prognosis and quality of life for patients with chronic kidney disease . This is an opportunity to open up hope for many people with chronic kidney disease because for a long time there has not been much progress in treating the disease."
Chronic kidney disease (CKD) is a condition in which kidney function is reduced or stopped working, so it cannot eliminate toxins and excess fluid from the body. CKD can lead to a series of complications. When CKD progresses to end-stage kidney failure, the patient needs dialysis or a kidney transplant to maintain life.
People at high risk of chronic kidney disease are people with a history of or currently suffering from at least one of the following diseases: diabetes, hypertension, cardiovascular disease (heart failure, ischemic heart disease...), overweight, obesity, acute kidney failure, acute kidney injury, kidney stones, urolithiasis and systemic diseases.
In Vietnam, it is estimated that about one in every 10 people has CKD and the incidence of CKD tends to increase over time. The demand for dialysis treatment is increasing while the number of hemodialysis units and dialysis service providers can only meet 30% of demand nationwide.
According to statistics, in 2019, the cost of CKD management was higher than the average GDP per capita, and the cost of dialysis was 4 times higher than the cost of treating early-stage chronic kidney disease. Because of the above burdens and consequences, screening, early detection and timely treatment for CKD patients will help slow down the process of kidney function decline, prevent the progression of the disease to alternative treatment. thereby bringing significant benefits to the medical industry.
